Edwin Tan
Companies that grabbed headlines in the deals space include:
AbbVie (NYSE:ABBV) has agreed to acquire all outstanding equity of neuroscience-focused biotech Aliada Therapeutics for $1.4B in cash.
Stericycle (NASDAQ:SRCL) disclosed that all the closing conditions for its planned $ 62-a-share sale to Waste Management (NYSE:WM) have been received.
Maersk (OTCPK:AMKBY) CEO Vincent Clerc said the shipping and logistics company won't be participating in the GXO Logistics (NYSE:GXO) sales process.
Blackstone (NYSE:BX) is the mystery investor who bid for a $7 billion minority stake in Roger Communication Inc.'s (NYSE:RCI) cell phone infrastructure business.
Siemens (OTCPK:SIEGY) (OTCPK:SMAWF) agreed to buy Altair Engineering (NASDAQ:ALTR) for $113 a share in cash, or a total deal value of $10.6 billion, the companies announced Wednesday.
Take-Two Interactive (NASDAQ:TTWO) ticks higher on report it's in talks to sell adtech division.
Cleveland-Cliffs (NYSE:CLF) said it won the final approvals needed for its planned $2.5 billion purchase of Stelco (OTCPK:STZHF) and the deal is scheduled to close on Friday.
GSK (NYSE:GSK) has agreed to acquire lupus drug candidate CMG1A46 from Chimagen Biosciences for $300M upfront plus potential milestone payments of up to $550M.
GlycoMimetics (NASDAQ:GLYC) soared 155% in premarket trade after it said it has entered into an acquisition agreement with privately-held firm, Crescent Biopharma.
Rapid7 (NASDAQ:RPD) surged 4.5% after a report that it's exploring options after getting takeover interest from private equity shops.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.